ANTX
ANTX
US0373261058
AN2 Therapeutics, Inc.
Loading chart...

Company Profile

-

Related stocks

CBIO
CBIO • United States
Crescent Biopharma, Inc.
14.91 USD
553.86M USD 1Y +17.1%
SGP
SGP • United States
SpyGlass Pharma, Inc.
24.92 USD
833.52M USD
JBIO
JBIO • United States
Jade Biosciences, Inc.
14.39 USD
915.17M USD 1Y +55.8%
ODTX
ODTX • United States
Odyssey Therapeutics, Inc.
19 USD
913.11M USD
SPTX
SPTX • United States
Seaport Therapeutics, Inc.
18.15 USD
971.58M USD
AKTS
AKTS • United States
Aktis Oncology, Inc.
18.15 USD
1.01B USD
AVLN
AVLN • United States
Avalyn Pharma Inc.
25.76 USD
1.14B USD
TRAX
TRAX • United States
First Tracks Biotherapeutics, I
31.85 USD
1.14B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
4 Metrics
Country
United States
Region
North America
Sector
Healthcare
Industry
Biotechnology

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
113.2% p.a.
Max Drawdown (5Y)
-95.6%
Sharpe Ratio (5Y)
-0.23
Beta Factor
-0.98
Size Class
Micro Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (113.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -95.6% in the extended horizon.
ende